PORTAGE BIOTECH INC. news, videos and press releases
For more news please use our advanced search feature.
PORTAGE BIOTECH INC. - More news...
PORTAGE BIOTECH INC. - More news...
- Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
- Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
- Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
- Portage Biotech Announces Completion of $2.15 Million Private Financing
- Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
- Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd
- Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
- Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update
- Portage Biotech Announces 1-for-20 Reverse Stock Split
- Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
- Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
- Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
- Portage Biotech Reports Business and Strategic Update
- Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
- Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Portage Biotech Announces $6.0 Million Registered Direct Offering
- Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
- Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
- Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
- Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
- Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
- Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting
- Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
- Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
- Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
- Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
- Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
